Volume 11, Number 6—June 2005
Rifampicin Resistance in Tuberculosis Outbreak, London, England
|Fragment||Amplicon size||Primer position||Primers|
|1||697 bp||–135 to –112* 541–562||Forward 5´ GTT TAG TTG CGT GCG TGC Reverse 5´ CTTGTCAAT GGT CTC GTC GAA|
|2||688 bp||451–472 1119–1139||Forward 5´ TTC CCG ATG ATG ACC GAG AAG Reverse 5´ GGA TCA GCT CGC CGA CCG TA|
|3||706 bp||1029–1048 1714–1735||Forward 5´ CGA GGG TCA GAC CAC GAT G Reverse 5´ GCG GGG CGA GAC GTC CAT GTA|
|4||681 bp||1624–1645 2284–2305||Forward 5´ ATC GAT GCG GAC GGT CGC TTC Reverse 5´ CGG GAT GTC GCG GGT GAT CTC|
|5||811 bp||2194–2215 2887–3005||Forward 5´ TCC AAC CGC CTG GTC GAA GAG Reverse 5´ CGT CGA CAC AAT GGC GTT|
|6||847 bp||2797–2815 +113 to +135*||Forward 5´ TGT GCC CAC AGC GGC TGG Reverse 5´ CTT TTT GAC CTC GCC ATA GGA C|
*Denotes a primer position in the sequence before the start (–) or after the end (+) of the rpoB gene sequence.
Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.